Oxidative Stress Markers in Heart Failure II
This study sets out to validate a simple, inexpensive blood test to identify Diastolic dysfunction (DD). Currently, diagnosis depends on costly, time-consuming imaging procedures that are only undertaken after symptoms develop. We have shown in the heart tissues of DD animals (mice and monkeys) and humans that S-glutathionylated cardiac myosin binding protein C (cMyBP-C) is likely responsible for reduced relaxation in DD and is elevated in the blood of each species when DD is present. Specific to the heart, cMyBP-C has been developed as a blood test to predict myocardial infarction. We hypothesize that modified S-glutathionylated cMyBP-C will be a blood marker for DD. We propose to do a non-interventional human clinical study to validate our animal and preliminary human data.
• Looking for both healthy and diastolic dysfunction participants who have had an echo in the past 6 months
• Age greater than or equal to 18 years
• Transthoracic echocardiogram within 1 year prior to enrollment containing tissue Doppler, mitral inflow velocities, left ventricular ejection fraction and left ventricular end‐diastolic volume index data
• Able to provide written consent
• Healthy patients with an E/e’ ratio < 15
• Patients with asymptomatic diastolic dysfunction with an E/e’ ratio > 15
• Able to give a blood sample
• EF greater than or equal to 50%
• EF<50%
• Any regional wall motion defects, any valvular heart disease with greater than a mild stenosis or regurgitation, any congenital or other significant structural heart disease,
• Patients undergoing cancer treatment
• Patients with an anticipated life expectancy less than 18 months.
• Age < 75 years
• Previous hospital admission for acute heart failure
• History of NYHA Class II, III or IV functional status
• The need for loop diuretics specifically for heart failure at any time.
• History of congestive heart failure.
• History of coronary artery disease.
• History of myocardial infarction.
• Significant structural heart disease
• Evidence of infiltrative cardiac disease
• Atrial fibrillation (AF) within 6 weeks
• Rhythm other than sinus at enrollment
• Patient with a pacemaker
• Cardiogenic shock
• History of heart transplant or left ventricular assist device
• Hemodialysis or peritoneal dialysis
• Active infection including bacteremia
• Major trauma or surgery within 6 weeks
• Collagen vascular disease if on active treatment including steroids and other immunomodulating drugs
• Systemic steroid use within 6 week.
Heart & Vascular
cardiac diastolic dysfunction (DD), Clinics and Surgery Center (CSC), cMyBP-C, Heart failure, HFpEF